Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-067554
Filing Date
2025-05-09
Accepted
2025-05-09 08:42:30
Documents
90
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sabs-20250331.htm   iXBRL 10-Q 2318941
2 EX-31.1 sabs-ex31_1.htm EX-31.1 26549
3 EX-31.2 sabs-ex31_2.htm EX-31.2 26630
4 EX-32.1 sabs-ex32_1.htm EX-32.1 11301
5 EX-32.2 sabs-ex32_2.htm EX-32.2 11644
  Complete submission text file 0000950170-25-067554.txt   11438365

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20250331.xsd EX-101.SCH 1725223
93 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20250331_htm.xml XML 2198636
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39871 | Film No.: 25928524
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)